文献速递神经肿瘤神经重症

纳武利尤单抗联合或不联合伊匹木单抗治疗儿童高级别中枢神经系统恶性肿瘤:安全性、疗效、生物标志物与药代动力学-CheckMate 908

Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
PubMed 文献 · Neuro Oncol · 2023-01-01

CheckMate 908 是一项开放标签、序贯臂的 1b/2 期研究,纳入 166 例儿童高级别中枢神经系统恶性肿瘤患者,评估纳武利尤单抗(NIVO)单药或联合伊匹木单抗(IPI)的疗效与安全性。结果显示,新诊断弥漫性内生型桥脑胶质瘤(DIPG)的中位 OS 分别为 11.7 个月(NIVO)和 10.8 个月(NIVO+IPI),各复发/进展队列的中位 PFS 均较短;NIVO±IPI 相较历史数据未显示临床获益,安全性总体可控,未发现新的安全性信号。

要点

  • 新诊断 DIPG 中位 OS:NIVO 11.7 个月 vs NIVO+IPI 10.8 个月。
  • 复发/进展高级别胶质瘤中位 PFS:NIVO 1.7 个月 vs NIVO+IPI 1.3 个月。
  • 3/4 级治疗相关不良事件率:NIVO 14.1% vs NIVO+IPI 27.2%。

核心结论

  • NIVO±IPI 相较历史数据未显示临床获益,总体安全性可控,未发现新的安全性信号。

研究设计与样本

  • CheckMate 908(NCT03130959)是一项开放标签、序贯臂的 1b/2 期研究,纳入 166 例儿童高级别中枢神经系统恶性肿瘤患者,分 5 个队列。
  • NIVO 3 mg/kg 每 2 周一次,或 NIVO 3 mg/kg + IPI 1 mg/kg 每 3 周一次(共 4 剂)后予 NIVO 3 mg/kg 每 2 周一次。
  • 主要终点为新诊断 DIPG 的总生存期(OS)及其他复发/进展或复发/难治 CNS 队列的无进展生存期(PFS)。

主要发现

  • 截至 2021 年 1 月 13 日,新诊断 DIPG 中位 OS(80% CI):NIVO 11.7(10.3-16.5)个月 vs NIVO+IPI 10.8(9.1-15.8)个月。
  • 复发/进展高级别胶质瘤中位 PFS(80% CI):NIVO 1.7(1.4-2.7)个月 vs NIVO+IPI 1.3(1.2-1.5)个月。
  • 复发/难治髓母细胞瘤中位 PFS(80% CI):NIVO 1.4(1.2-1.4)个月 vs NIVO+IPI 2.8(1.5-4.5)个月。
  • 复发/难治室管膜瘤中位 PFS(80% CI):NIVO 1.4(1.4-2.6)个月 vs NIVO+IPI 4.6(1.4-5.4)个月。
  • 其他复发/进展 CNS 肿瘤中位 PFS(95% CI):NIVO 1.2(1.1-1.3)个月 vs NIVO+IPI 1.6(1.3-3.5)个月。

关键数值与推荐

  • 3/4 级治疗相关不良事件率:NIVO 14.1% vs NIVO+IPI 27.2%。
  • NIVO 和 IPI 首剂谷浓度在年龄最小和体重最低的患者中更低。
  • 基线肿瘤 PD-L1 表达与生存无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic options are limited in pediatric CNS malignancies. CheckMate 908 (NCT03130959) is an open-label, sequential-arm, phase 1b/2 study investigating nivolumab (NIVO) and NIVO + ipilimumab (IPI) in pediatric patients with high-grade CNS malignancies. METHODS: Patients (N = 166) in 5 cohorts received NIVO 3 mg/kg every 2 weeks (Q2W) or NIVO 3 mg/kg + IPI 1 mg/kg every 3 weeks (4 doses) followed by NIVO 3 mg/kg Q2W. Primary endpoints included overall survival (OS; newly diagnosed diffuse intrinsic pontine glioma [DIPG]) and progression-free survival (PFS; other recurrent/progressive or relapsed/resistant CNS cohorts). Secondary endpoints included other efficacy metrics and safety. Exploratory endpoints included pharmacokinetics and biomarker analyses. RESULTS: As of January 13, 2021, median OS (80% CI) was 11.7 (10.3-16.5) and 10.8 (9.1-15.8) months with NIVO and NIVO + IPI, respectively, in newly diagnosed DIPG. Median PFS (80% CI) with NIVO and NIVO + IPI was 1.7 (1.4-2.7) and 1.3 (1.2-1.5) months, respectively, in recurrent/progressive high-grade glioma; 1.4 (1.2-1.4) and 2.8 (1.5-4.5) months in relapsed/resistant medulloblastoma; and 1.4 (1.4-2.6) and 4.6 (1.4-5.4) months in relapsed/resistant ependymoma. In patients with other recurrent/progressive CNS tumors, median PFS (95% CI) was 1.2 (1.1-1.3) and 1.6 (1.3-3.5) months, respectively. Grade 3/4 treatment-related adverse-event rates were 14.1% (NIVO) and 27.2% (NIVO + IPI). NIVO and IPI first-dose trough concentrations were lower in youngest and lowest-weight patients. Baseline tumor programmed death ligand 1 expression was not associated with survival. CONCLUSIONS: NIVO ± IPI did not demonstrate clinical benefit relative to historical data. The overall safety profiles were manageable with no new safety signals.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Dunkel IJ, Doz F, Foreman NK, et al. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. Neuro Oncol. 2023. PMID: 36808285. doi:10.1093/neuonc/noad031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。